TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8306006

Group type: EXPERIMENTAL
Intervention: Intervention group (individualized feedback and preceptor guidance)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Librarian searches
Number of subjects: 311
Study: 2881183

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol + Nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol + Nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beta-blocker
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapy (Beta-blockade + Nifedipine)
Number of subjects: 12
Study: 30958141

Group type: EXPERIMENTAL
Intervention: Stress reduction intervention (5-weekly sessions)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 54
Study: 29551546

Group type: EXPERIMENTAL
Intervention: Music intervention programme (listening to traditional music and playing musical instruments) three times a week for twelve weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Music intervention programme
Number of subjects: 77
Study: 27181070

Group type: EXPERIMENTAL
Intervention: 0.5 U/kg IDegAsp
Number of subjects: 21

Group type: COMPARATOR
Intervention: biphasic insulin aspart 30
Number of subjects: 21
Study: 25919069

Group type: EXPERIMENTAL
Intervention: Gastric Bypass (GB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 50
Study: 23848405

Group type: COMPARATOR
Intervention: 1 μg.kg(‐1) intranasal dexmedetomidine with 3 mg.kg(‐1) oral ketamine (Group 1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 1 μg.kg(‐1) intranasal dexmedetomidine with 5 mg.kg(‐1) oral ketamine (Group 2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 2 μg.kg(‐1) intranasal dexmedetomidine with 3 mg.kg(‐1) oral ketamine (Group 3)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 2 μg.kg(‐1) intranasal dexmedetomidine with 5 mg.kg(‐1) oral ketamine (Group 4)
Number of subjects: 160
Study: 21037344

Group type: EXPERIMENTAL
Intervention: Hip resurfacing
Number of subjects: 59

Group type: COMPARATOR
Intervention: Total hip replacement
Number of subjects: 59
Study: 18071725

Group type: EXPERIMENTAL
Intervention: Involved skin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clinically non-lesional skin
Number of subjects: 69
Study: 16875157

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia (IAWBC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 100
Study: 12694974

Group type: EXPERIMENTAL
Intervention: Thermochoice endometrial thermal ablation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mirena LNG-IUS
Number of subjects: 50
Study: 10374098

Group type: EXPERIMENTAL
Intervention: Individual culture group (78 cycles)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Group culture group (81 cycles)
Number of subjects: 159
Study: 8914773

Group type: EXPERIMENTAL
Intervention: HIV‐1MN recombinant gp120 (rgp120) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV‐1MN recombinant gp120 (rgp120) vaccine with HIV‐1IIIB rgp120 vaccine
Number of subjects: 0
Study: 2056136

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 6881177

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (intravenous bolus of methylprednisolone followed by an eight-day tapering course of oral methylprednisolone starting at 32 mg twice a day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 76
Study: 29232351

Group type: EXPERIMENTAL
Intervention: Intraurethral 2% lidocaine jelly administered via Uro‐Jet, 5 minutes before TUBC.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (no analgesia).
Number of subjects: 80
Study: 26397935

Group type: EXPERIMENTAL
Intervention: Food insufficiency
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Higher pretreatment HIV‐1 RNA
Number of subjects: 171

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 171
Study: 24055512

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted wound closure (VAC) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alginate (Sorbalgon) therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both VAC and alginate groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alginate therapy
Number of subjects: 20
Study: 22429343

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C plus 10 mg zinc
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 20001651

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 102

Group type: COMPARATOR
Intervention: Montelukast and Fluticasone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Pre-bronchodilatory FEV1
Number of subjects: 102

Group type: COMPARATOR
Intervention: Airway reversibility
Number of subjects: 102
Study: 19076086

Group type: EXPERIMENTAL
Intervention: Multicenter randomized trials and novel classes of drugs and interventional catheter technologies
Number of subjects: 0
Study: 15919685

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (non-anthracycline-based)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: N+ HR- elderly patients
Number of subjects: 260
Study: 12663356

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) on both quadriceps muscles with a frequency of 45-60 Hz, 12 seconds of stimulation followed by eight seconds recovery for a total of 30 minutes a day, three days a week for six weeks
Number of subjects: 15
Study: 10889132

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR(c))
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Use of angiotensin-converting enzyme inhibitors
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: N-terminal atrial natriuretic peptide (ANP)
Number of subjects: 1906
Study: 8821417

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Streptokinase without further treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Failed infarct-related artery recanalization
Number of subjects: 30
Study: 1431255

Group type: EXPERIMENTAL
Intervention: HA-1A (100 mg intravenous single dose)
Number of subjects: 82
Study: 2861218

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 35

Group type: COMPARATOR
Intervention: pindolol
Number of subjects: 35

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 35
Study: 31050833

Group type: EXPERIMENTAL
Intervention: Aspirin at doses below 75 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants at doses 1/4 of those recommended for atrial fibrillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower doses of antithrombotics than currently recommended
Number of subjects: 0
Study: 30566498

Group type: EXPERIMENTAL
Intervention: LEAPS programme delivered by trained female youth
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 340
Study: 27619783

Group type: EXPERIMENTAL
Intervention: Electronic micturition chart (EMC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pen and paper micturition chart (MC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both EMC and MC
Number of subjects: 29
Study: 24819710

Group type: EXPERIMENTAL
Intervention: Stepwise protocol of treating pain (SPTP) with acetaminophen, morphine, buprenorphine transdermal patch, and pregabalin for 8 weeks
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352
Study: 22981558

Group type: EXPERIMENTAL
Intervention: Cryoplasty balloon post-dilation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional balloon post-dilation
Number of subjects: 74
Study: 20959429

Group type: EXPERIMENTAL
Intervention: BIBN4096BS (olcegepant) 10 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16984942

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX alone (Control)
Number of subjects: 0
Study: 16260986

Group type: EXPERIMENTAL
Intervention: Aquatic plyometric training (APT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Flexibility exercises (CON)
Number of subjects: 19
Study: 10688397

Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TOBI) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 9778488

Group type: EXPERIMENTAL
Intervention: Low dose inhaled fluticasone propionate (250 mcg bd)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23
Study: 8105814

Group type: EXPERIMENTAL
Intervention: Early neuroleptic intervention treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 0
Study: 3536947

Group type: EXPERIMENTAL
Intervention: Preincisional presternal antibiotic infiltration (2%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline infiltration (control)
Number of subjects: 100
Study: 30124723

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% foam (Cal/BD)
Number of subjects: 25
Study: 27133971

Group type: EXPERIMENTAL
Intervention: Universal pre-procedural indometacin (100 mg rectal indometacin within 30 min before ERCP)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Risk-stratified post-procedural indometacin (only high-risk patients received indometacin immediately after ERCP)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Universal pre-procedural indometacin
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Risk-stratified post-procedural indometacin
Number of subjects: 2600
Study: 24184292

Group type: EXPERIMENTAL
Intervention: Luminette®
Number of subjects: 25

Group type: COMPARATOR
Intervention: No light therapy (after Luminette® use)
Number of subjects: 25
Study: 21471500

Group type: EXPERIMENTAL
Intervention: Financial incentives (modest bonuses equal to about 5 percent of a physician's salary)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: System-level incentives (increased compensation to hospitals and across groups of physicians)
Number of subjects: 30
Study: 18378381

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dietary modification
Number of subjects: 81

Group type: COMPARATOR
Intervention: No statin therapy (Control group)
Number of subjects: 81
Study: 16685353

Group type: EXPERIMENTAL
Intervention: Ultrasonic atomization of Shaduolika and dexamethasone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Niuhuangjiedu tablets (control)
Number of subjects: 84
Study: 14533985

Group type: EXPERIMENTAL
Intervention: rhu‐GM‐CSF (125mg/M(2)) injected subcutaneously twice weekly for four weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rhu‐GM‐CSF
Number of subjects: 31
Study: 10943575

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone (30 microg ethinylestradiol and 3 mg drospirenone)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Ethinylestradiol/desogestrel (150 microg desogestrel)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone
Number of subjects: 900

Group type: COMPARATOR
Intervention: Ethinylestradiol/desogestrel
Number of subjects: 900
Study: 9171791

Group type: EXPERIMENTAL
Intervention: Spiral CT angiography (SCTA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional transfemoral angiography
Number of subjects: 30
Study: 1544778

Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acetazolamide 500 mg vs Placebo
Number of subjects: 20
Study: 3534203

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanate (40 mg/kg amoxicillin plus 10 mg/kg clavulanate, total daily doses in three divided doses)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg)
Number of subjects: 68
Study: 29896235

Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion (control)
Number of subjects: 86
Study: 27454547

Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/d
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 412

Group type: COMPARATOR
Intervention: Lurasidone 20 mg/d
Number of subjects: 412
Study: 24977985

Group type: EXPERIMENTAL
Intervention: InflammaDry test with OSDI included
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: InflammaDry test without OSDI
Number of subjects: 237
Study: 22628033

Group type: EXPERIMENTAL
Intervention: 3D‐HRM assembly
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3D‐eSleeve
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard eSleeve
Number of subjects: 39
Study: 20483968

Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1004
Study: 18509289

Group type: EXPERIMENTAL
Intervention: ODI category group N (ODI= or <5 events/hour), N=9
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ODI category group A (5<ODI= or <15 events/hour), N=14
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ODI category group B (ODI>15 events/hour), N=6
Number of subjects: 29
Study: 20508073

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 1.0 microg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 2.25 microg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 4.5 microg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FACT-fatigue subscale
Number of subjects: 0
Study: 16298657

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 241
Study: 12452404

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299V
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9677810

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 7929868

Group type: EXPERIMENTAL
Intervention: 100 mg of controlled-release metoprolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 100 mg of atenolol
Number of subjects: 60
Study: 2889495

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 46

Group type: COMPARATOR
Intervention: Flupenthixol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pimozide and Flupenthixol
Number of subjects: 46
Study: 31870605

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus financial incentives
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 360
Study: 29941478

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 27578562

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Intravenous labetalol
Number of subjects: 147
Study: 23471837

Group type: EXPERIMENTAL
Intervention: Promotion of increased breastfeeding duration and exclusivity (experimental intervention)
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Control arm (standard breastfeeding practices and policies)
Number of subjects: 17046

Group type: EXPERIMENTAL
Intervention: Follow-up at age 6.5 years (PROBIT II)
Number of subjects: 17046

Group type: EXPERIMENTAL
Intervention: Follow-up at age 11.5 years (PROBIT III)
Number of subjects: 17046
Study: 22810476

Group type: EXPERIMENTAL
Intervention: Perianal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Endoanal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Perianal administration
Number of subjects: 52

Group type: COMPARATOR
Intervention: Endoanal administration
Number of subjects: 52
Study: 19955824

Group type: EXPERIMENTAL
Intervention: Cinacalcet for 6 months in group S (gland <500 mm(3))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cinacalcet for 6 months in group L (gland >=500 mm(3))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cinacalcet for 6 months in both groups S and L
Number of subjects: 24
Study: 18237841

Group type: EXPERIMENTAL
Intervention: Retrojugular access
Number of subjects: 600

Group type: COMPARATOR
Intervention: Ventrojugular access
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 600
Study: 15545508

Group type: EXPERIMENTAL
Intervention: COX‐2‐specific inhibitors
Number of subjects: 11000000
Study: 12854788

Group type: EXPERIMENTAL
Intervention: Bar-clip mechanism
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ball attachments
Number of subjects: 100
Study: 10565580

Group type: EXPERIMENTAL
Intervention: High-information preparation condition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-information preparation condition
Number of subjects: 100
Study: 8767599

Group type: EXPERIMENTAL
Intervention: Physical training + low-dose heparin calcium (12,500 IU/day for 6 months)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 374
Study: 1751265

Group type: EXPERIMENTAL
Intervention: Low dose lignocaine (mean plasma concentration 0.92 micrograms ml‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose lignocaine (mean plasma concentration 1.78 micrograms ml‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lignocaine (both doses)
Number of subjects: 9
Study: 6284651

Group type: EXPERIMENTAL
Intervention: Pivmecillinam and pivampicillin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 22
Study: 31801427

Group type: EXPERIMENTAL
Intervention: ReSi‐Kompetenzförderprogramm
Number of subjects: 412
Study: 26362760

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with peanut for 12 months
Number of subjects: 33
Study: 25321447

Group type: EXPERIMENTAL
Intervention: Endobronchial therapy (treatment group)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Sham procedure (control group)
Number of subjects: 277
Study: 22633007

Group type: EXPERIMENTAL
Intervention: Shoe sole-embedded apparatus for randomly perturbing the stance phase of gait
Number of subjects: 6
Study: 20001969

Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium) infusion
Number of subjects: 22
Study: 18312520

Group type: EXPERIMENTAL
Intervention: Infusion injection of rocuronium (I0.6, I0.9)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bolus injection of rocuronium (B0.6, B0.9)
Number of subjects: 120
Study: 15670545

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (various doses)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Atorvastatin (various doses)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Simvastatin (various doses)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Pravastatin (various doses)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Overall treatment with rosuvastatin, atorvastatin, simvastatin, and pravastatin
Number of subjects: 811
Study: 14746860

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) at a dose of 80 mg/m(2) every 14 days for four courses, followed by delayed surgery and two more similar CDDP courses for SR-HB patients.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) alternating every 14 days with carboplatin (CARBO), 500 mg/m(2), and doxorubicin (DOXO), 60 mg/m(2) for HR-HB patients.
Number of subjects: 135
Study: 10693095

Group type: EXPERIMENTAL
Intervention: Supine positioning
Number of subjects: 22

Group type: COMPARATOR
Intervention: Prone positioning
Number of subjects: 22
Study: 9092746

Group type: EXPERIMENTAL
Intervention: Glycolic acid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jessner's solution treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wood's light examination
Number of subjects: 0
Study: 8250708

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg bolus followed by 37.5 mg/h)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sucralfate (1 g every 6 hours suspended in 20 mL of sterile water)
Number of subjects: 114
Study: 3080867

Group type: EXPERIMENTAL
Intervention: Lipid-supplemented group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lipid-restricted group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Initial plasma choline concentrations in malnourished patients
Number of subjects: 25
Study: 31002812

Group type: EXPERIMENTAL
Intervention: VR combined real instrument training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 31
Study: 29378718

Group type: EXPERIMENTAL
Intervention: Clofazimine (CLO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 26762204

Group type: EXPERIMENTAL
Intervention: Bevacizumab (beva) + CCNU chemotherapy
Number of subjects: 0
Study: 24635342

Group type: EXPERIMENTAL
Intervention: AEX+WL
Number of subjects: 77

Group type: COMPARATOR
Intervention: WL
Number of subjects: 77